SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: DRS/A
Document Type: DRS/A
Date Filed: 2025-10-06
Accession Number: 0001493152-25-016953
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315225016953/filename1.htm

Chunk 51 of 87
Word Count: 1482
Character Count: 10028

Document Content:

at the discretion of the board of directors until their successors are duly elected and qualified, unless sooner removed. Our board of directors is authorized to appoint officers to the offices set forth in our bylaws. Director Independence The Nasdaq listing standards require that a majority of our board of directors be independent. An “independent director” is defined generally as a person who has no material relationship with the listed company (either directly or as a partner, shareholder or officer of an organization that has a relationship with our company). We have three “independent directors” as defined in the Nasdaq listing standards and applicable SEC rules prior to completion of this offering. Our board has determined that Mark Ravich, Rishi Puri and William Abraham are independent directors under applicable SEC and Nasdaq rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Board Committees

Our
board of directors has established an Audit Committee, a Nominating and Corporate Governance Committee and a Compensation Committee.
Our board of directors has adopted a charter for each of these three committees. Prior to the completion of this offering, copies of
each committee’s charter will be posted on the Investor Relations section of our website, which will be located at www.bioventrix.com.
Each of the committees of our board of directors shall have the composition and responsibilities described below. Our board of directors
may from time to time establish other committees as it deems appropriate.

Audit
Committee

Ravich, Dr. Abraham and Dr. Puri will serve as members of our Audit Committee with Mr. Ravich serving as the chairman of the Audit
Committee. Each of our Audit Committee members will
satisfy the “independence” requirements of the Nasdaq listing rules and meet the independence standards under Rule 10A-3
under the Exchange Act. Our board of directors has determined that Mark Ravich possesses accounting or related financial management experience
that qualifies her as an “audit committee financial expert” as defined by the rules and regulations of the SEC. Our Audit
Committee oversees our accounting and financial reporting processes and the audits of our financial statements. Our Audit Committee will
perform several functions, including:

●	evaluating
the performance, independence and qualifications of our independent registered public accounting firm and determining whether to
retain our existing independent registered public accounting firm or engage new independent registered public accounting firm;

●	reviewing
and approving the engagement of our independent registered public accounting firm to perform audit services and any permissible non-audit
services;

●	reviewing
our annual and quarterly financial statements and reports, including the disclosures contained under the caption “ Management’s
Discussion and Analysis of Financial Condition and Results of Operations ,” and discussing the statements and reports with
our independent registered public accounting firm and management;

●	reviewing
with our independent registered public accounting firm and management significant issues that arise regarding accounting principles
and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls;

●	reviewing
our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk
management is implemented; and

●	reviewing
and evaluating on an annual basis the performance of the audit committee, including compliance of the audit committee with its charter.

Compensation
Committee

Ravich, Dr. Abraham and Dr. Puri will serve as members of our Compensation Committee with Mr. Ravich serving as the chairman of the
Compensation Committee. All of our Compensation
Committee members satisfy the “independence” requirements of the Nasdaq listing rules and meet the independence standards
under Rule 10A-3 under the Exchange Act. The functions of this committee include, among other things:

●	reviewing,
modifying and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) our overall
compensation strategy and policies;

●	reviewing and approving the compensation, the performance goals and objectives relevant to the compensation, and other terms of employment
of our executive officers;

●	reviewing
and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) the equity incentive
plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and
programs;

●	reviewing
and approving the terms of any employment agreements, severance arrangements, change in control protections and any other compensatory
arrangements for our executive officers;

●	reviewing
with management and approving our disclosures under the caption “ Compensation Discussion and Analysis ” in our
periodic reports or proxy statements to be filed with the SEC; and

●	preparing
the report that the SEC requires in our annual proxy statement.

Nominating
and Corporate Governance Committee

Ravich, Dr. Abraham, and Dr. Puri will serve as members of our Nominating and Corporate Governance Committee with Mr. Ravich serving
as the chairman of the Nominating and Corporate Governance Committee.
All of our Nominating and Corporate Governance Committee members will satisfy the “independence” requirements of the Nasdaq
listing rules and meet the independence standards under Rule 10A-3 under the Exchange Act. The functions of this committee include, among
other things:

●	identifying,
reviewing and evaluating candidates to serve on our board of directors consistent with criteria approved by our board of directors;

●	evaluating
director performance on the board and applicable committees of the board and determining whether continued service on our board is
appropriate;

●	evaluating,
nominating and recommending individuals for membership on our board of directors; and

●	evaluating
nominations by stockholders of candidates for election to our board of directors.

The
nominating and corporate governance committee will take into account many factors in determining recommendations for persons to serve
on the board of directors, including the following:

●	personal
and professional integrity, ethics and values;

●	experience
in corporate management, such as serving as an officer or former officer of a publicly-held company;

●	experience
as a board member or executive officer of another publicly-held company;

●	strong
finance experience;

●	diversity
of expertise and experience in substantive matters pertaining to our business relative to other board members;

●	diversity
of background and perspective including, without limitation, with respect to age, gender, race, place of residence and specialized
experience;

●	experience
relevant to our business industry and with relevant social policy concerns; and

●	relevant
academic expertise or other proficiency in an area of our business operations.

Role
of Board in Risk Oversight Process

Periodically,
our board of directors assesses these roles and the board of directors leadership structure to ensure the interests of our company and
our stockholders are best served. Our board of directors has determined that its current leadership structure is appropriate.

While
management is responsible for assessing and managing risks to our company, our board of directors is responsible for overseeing management’s
efforts to assess and manage risk. This oversight is conducted primarily by our full board of directors, which has responsibility for
general oversight of risks, and standing committees of our board of directors. Our board of directors satisfies this responsibility through
full reports by each committee chair regarding the committee’s considerations and actions, as well as through regular reports directly
from officers responsible for oversight of particular risks within our company. Our board of directors believes that full and open communications
between management and the board of directors are essential for effective risk management and oversight.

Compensation
Committee Interlocks and Insider Participation

None
of our executive officers serves, or in the past has served, as a member of the board of directors or compensation committee, or other
committee serving an equivalent function, of any entity that has one or more executive officers who serve as members of our board of
directors or our compensation committee. None of the members of our compensation committee is, or has ever been, an officer or employee
of our company.

Clawback
Policy

will adopt a compensation recovery policy that is compliant with Nasdaq listing rules as required by the Dodd-Frank Act.

Code
of Business Conduct and Ethics

or prior to the completion of this offering, we will adopt a written code of business conduct and ethics that applies to our employees,
officers and directors. A current copy of the code will be posted on the Corporate Governance section of our website, which will be located
at www.bioventrix.com. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics,
or waivers of such provisions applicable to any principal executive officer, principal financial officer, principal accounting officer
or controller, or persons performing similar functions, and our directors, on our website identified above or in filings with the SEC.

Involvement
in Certain Legal Proceedings

Except
as otherwise disclosed below in paragraph (a), to the best of our knowledge, none of our directors or executive officers has, during
the past ten years:

●	been
convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor
offenses);